Bluebird, Celgene to share U.S. costs, profits on lead cancer CAR-T

Bluebird stands to collect up to $70 million in milestone payments for bb2121's first indication, and could pick up more from a potential second indication. (Gerd Altmann)

Bluebird bio has pulled the trigger on an option to co-develop and co-promote the anti-BCMA CAR-T treatment, bb2121, with Celgene in the U.S. The move comes two years after Celgene forked over $10 million to exclusively license the therapy.

The pair entered a global research pact in 2013 to discover, develop and commercialize novel cancer treatments. That included bb2121, which adds a B-cell maturation antigen (BCMA)-chimeric antigen receptor to patients' T cells.

Now, starting in April, they will share U.S. costs and profits evenly, including those associated with the ongoing phase 1 clinical study of bb2121, as well as the commercialization and manufacturing of the treatment within the U.S.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Under the agreement, Bluebird stands to collect up to $70 million in development milestones for bb2121’s first indication, relapsed and refractory multiple myeloma. It has the potential to pick up more milestone payments from a second indication and modified licensed products, the company said in an 8-K filing. It will also receive ex-U.S. royalties on the treatment.

“Entering into this co-development and co-promotion partnership with Celgene is a significant step forward in building a fully integrated oncology franchise for bluebird and together, we are committed to rapidly advancing development of bb2121 for patients,” said Joanne Smith-Farrell, oncology franchise leader and senior vice president, corporate development and strategy at Bluebird.

RELATED: ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data

“The collaboration builds upon our extensive research and development capabilities in oncology and is a testament to the strong partnership that exists between our two companies.” Bluebird and Celgene are also collaborating on a second multiple myeloma candidate, bb21217

Bluebird reported data from the CRB-401 phase 1 trial of bb2121 in December showing impressive overall and complete response rates to the treatment—94% and 56% respectively—despite the patients having late-stage multiple myeloma after having been treated with a median of seven earlier treatments.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.